LRMR

Several key events have impacted Larimar Therapeutics' stock price in the past six months. The FDA granted Breakthrough Therapy Designation to nomlabofusp, leading to a stock price surge. A $100 million public offering was completed, strengthening the company's balance sheet. The FDA provided positive feedback regarding a potential regulatory filing for nomlabofusp, with plans to submit a BLA in June 2026. Larimar Therapeutics reported its Fourth Quarter and Full Year 2025 financial results on March 19, 2026. Cross-species findings supporting skin as a surrogate for the measurement of frataxin in tissues clinically relevant to Friedreich's Ataxia were published. LRMR has outperformed the market in the last year and three months.